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Hypertension is a widely prevalent and important risk factor for cardiovascular diseases that increase with aging. The hallmark
of hypertension in the elderly is increased vascular dysfunction. However, the molecular mechanisms by which increased blood
pressureleadstovascularinjuryandimpairedendothelialfunctionarenotwelldeﬁned.Inthepresentpaper,wewillanalyzeseveral
mechanisms described in the scientiﬁc literature involved in hypertension in the elderly as endothelial dysfunction, increased
oxygen delivery to tissues, inﬂammation, cellular apoptosis, and increased concentration of active metabolites. Also, we will focus
on new molecular mechanisms involved in hypertension such as telomeres shortening, progenitor cells, circulating microparticles,
and epigenetic factors that have appeared as possible causes of hypertension in the elderly. These molecular mechanisms may
elucidate diﬀerent origin for hypertension in the elderly and provide us with new targets for hypertension treatment.
1.Introduction
The elderly, considered as individuals 65 years of age and
older, represents the most rapidly growing segment of the
population. Age is a powerful risk factor for hypertension,
death, and cardiovascular death [1]. In this regard, high
blood pressure in the elderly confers a three- to fourfold
increase in risk for cardiovascular disease, compared to
youngerindividuals[2].Newguidelineshavetriedtoprovide
evidence-based treatment algorithms in which control of
hypertension is just one aspect of general risk factor control,
with the aim of decreasing the total risk. According to the
World Health Organization, hypertension is the commonest
cause of preventable death in developed countries, and it is
increasingly signiﬁcant in developing countries. Particularly,
ithasbeendescribedthathypertensionaﬀectsmorethanone
half of those aged 65 and older, and its prevalence continues
being increased with age. The incidence of hypertension in
theelderlypopulation,overage60–65years,isveryhighwith
prevalenceashighas60%to80%.Itisestimatedthattwoout
of three individuals over 75 years of age suﬀer hypertension
[3].
Large number of studies has revealed that patterns of
hypertension change with age. In this regard, systolic blood
pressure increases, while diastolic blood pressure decreases
aftertheageof60.Thesediﬀerentpatternsindicateusdiverse
etiologic and hemodynamic mechanisms for hypertension
in the elderly population [4]. Several mechanisms involved
in hypertension in the elderly have been described in the
scientiﬁc literature as endothelial dysfunction, increased
oxygen delivery to tissues, increased concentration of active
metabolites or increased myogenic constriction. Recently,
new molecular mechanisms involved in hypertension such
as telomeres shortening and endothelial progenitors cells
have appeared as possible causes of hypertension in the
elderly. These molecular mechanisms may elucidate diﬀerent
origin for hypertension in the elderly and provide us with
new targets for hypertension treatment. This paper will be
focused in the management and old and new molecular
mechanisms associated with hypertension in the elderly.2 International Journal of Hypertension
2. Management of Hypertensionin the Elderly
Due to the advances in the treatment of hypertension, the
deﬁnition of isolated systolic hypertension has been changed
from a blood pressure level ≥160/<90 to ≥140/<90mmHg.
Initially, the focus of hypertension studies was only on
diastolic blood pressure. Later, multiple hypertension trials
demonstrated that systolic blood pressure (SBP) levels were
concomitantly lowered with diastolic blood pressure and
that SBP was more closely associated with improvements
in outcome than diastolic blood pressure, providing more
relevance to SBP.
High blood pressure, and in particular, isolated systolic
hypertension (ISH), has been in the elderly, as recently as
two decades, ignored as a cardiovascular risk factor [5]. In
1985, the European Working Party on High Blood Pressure
in the Elderly (EWPHE), provided the ﬁrst evidences about
the beneﬁts of the therapeutic intervention in the elderly
hypertensive patients [6]. However, it was not until the
1990 swhenitreallytookintoconsiderationthefactoftreat-
ing hypertension based solely on systolic pressure. In 1991,
the Systolic Hypertension in the Elderly Program (SHEP)
demonstrated in 4736 older individuals with SBP levels
>160mmHg and diastolic blood pressure levels <90mmHg,
randomized to treatment with thiazide-type diuretic-based
regimen versus placebo, greater reductions in blood pressure
in the treated group and reductions in the primary end point
by 36%, heart failure by 49%, and coronary events by 27%
[7].
In1997,theSystolicHypertensioninEuropeStudy(SYS-
TEUR) corroborated the results obtained in the SHEP study.
In the SYS-TEUR study a group of aging patients were
randomized to the dihydropyridine calcium channel blocker
nitrendipine or placebo. In this study, blood pressure was
not reduced as eﬀective as in SHEP. However, the beneﬁts
obtained were higher, showing a signiﬁcant reduction in
stroke by 42% [8].
The Hypertension in the Very Elderly Trial (HYVET)
is other remarkable trial of 3854 patients over 80 years
of age, who received a combination of indapamide and
perindopril. The study was stopped prematurely due to
the conclusive results showing that people who received
eﬀective antihypertensive treatment were at 74% less risk
of developing congestive heart failure and 20% or more at
less risk of developing a stroke or dying either from cardiac
complications or any other causes of death. These results
provided the clinical evidence supporting the most recent
guidelines for the treatment of hypertension [9].
3.Main Molecular Mechanisms Associated with
Hypertension and Aging
3.1. Vascular Aging: Endothelial Dysfunction. Arterial wall is
constituted for three layers: intima, media, and adventitia.
Media and especially intima layers are where major alter-
ations occur with age. Intima layer is based in a layer of
endothelial cells on a subendothelial space that is separated
from media layer due to elastic ﬁbers. Media layer is
formed by smooth muscle cells connected by extracellular
matrix, muscle cells are also responsible for releasing of
extracellularmatrixcomponentssuchascollagenandelastin.
In advancing age, lipids are internalized into elastin ﬁbers,
and they attract calcium ions that provoke loss of elasticity
and degradation of elastin ﬁbers due to elastases.
As Dr. Osler postulated, “A man is so old as his arteries”.
In this regard, recent studies have concluded that structure
and function of arteries change throughout the lifetime
of humans [10, 11]. So, it has been demonstrated that
in humans central elastic arteries as well as arterial wall
dilate with advancing age. In addition, a large number of
studies using animal models also found an age-associated
restructuring of the central arteries of rats, rabbits, and
primates [12, 13].
Endothelial cells play a central role in regulating several
arteries properties, such as releasing of nitric oxide (NO),
vascular tone, permeability, and, therefore, in the arterial
pressure. Nitric oxide is a multifunctional molecule with
an important role in the relationship between the cells that
compose the microvascular environment. Perhaps, the most
important eﬀect of NO is its vasodilating property [14].
NO provokes vasodilation by stimulating soluble guanylate
cyclase in the vascular smooth muscle cells [15]. Therefore,
alterations in the expression of NO synthase (NOS) isoforms
oritsfunctionalityhasbeenwidelyassociatedwithhyperten-
sion.
Age alters the amount, arrangement, and structural
integrity of the endothelial cells cytoskeleton, which
aﬀects the mobility, migration, proliferation, and structural
integrity of endothelial cells [16, 17]. At molecular level,
numerous studies have associated the age advancing with
decreased EC capacity for replication and increasing apopto-
sis, proinﬂammatory status and reduced production, and/or
bioavailability of NO (Figure 1).
3.2. Alterations in the Production and/or Bioavailability of
Nitric Oxide. Several vascular disorders, including a dimin-
ished endothelium-dependent relaxation, have been demon-
strated in aging humans and even in experimental animals
[18, 19]. Diﬀerent hypothesis have been raised to explain
the reduction of the endothelium-dependent vasodilatation
described in the aging humans and animals: a decreased
number of vasodilator receptors in the endothelium [20], a
diminished capability to generate NO by the endothelium
[19], and a reduction in guanylate cyclase activity in vascular
smooth muscle cells [21]. In this light of evidences, a study
performed by Cernadas et al. revealed new evidences about
the function of the NO-dependent vasorelaxing mechanisms
in aging rats [22]. They found in aging animals a reduced
vasorelaxing response to acetylcholine, an endothelium NO-
dependent vasodilator. However, paradoxically, blood vessels
from aging rats showed a marked capacity to produce NO
through the presence of the inducible NOS (iNOS) isoform.
This ﬁnding highlights the importance of the presence iNOS
isoform in aging, because at sites of endothelial damage,
the locally released cytokines, such as tumour necrosis alpha
(TNFα), could potentially stimulate iNOS expressed in theInternational Journal of Hypertension 3
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Figure 1: Known mechanisms involved in hypertension in the elderly population. Impairment of the NO/cGMP system, increased cellular
apoptosis, and increased concentration of active metabolites such as advanced glycation end products (AGEs) together with an enhanced
oxidative an inﬂammatory state are well-known mechanisms that contributes to the development of hypertension in the elderly population.
vascular wall. In this sense, continuous generation of NO
by iNOS has been associated with the impairment of the
NO system in endothelial cells which has been speculated to
protect the vascular wall from excessive amounts of NO. The
NO released by the iNOS activity could decrease the eNOS
activity, thus favoring the impaired endothelium-dependent
vasorelaxation. Indeed, NO has been also described as a
cytotoxic molecule for endothelium, inhibiting their growth
[23]. In addition, it is well known that free radicals,
which increase in aging, inactivate NO by interacting with
high concentrations of superoxide anion and resulting in
enhanced peroxynitrite formation. Therefore, iNOS may
have an important role in the maintenance of vascular tone
with increasing age.
Endothelial dysfunction occurs early in several cardio-
vascular disorders including atherosclerosis, diabetes, and
hypertension. Hypertensive subjects exhibit endothelial dys-
function, indicating that endothelial dysfunction precedes
the development of clinical hypertension. Systolic hyper-
tension is the dominant form of hypertension in older
individuals [24]. Arterial stiﬀness, determined by structural
properties of the blood vessel wall and by smooth muscle
tone, is one of the most important factors underlying the
increase in systolic pressure. In this regard, longitudinal
studies in humans have shown that arterial stiﬀness is an
independent predictor of the rise in systolic blood pressure
and of incident hypertension [25]. All these experimental
evidences reveal the stretch linkage between aging and
hypertension. Recently, a brilliant article performed by the
American Society of Hypertension Writing Group [26]r e c -
ognized the pivotal role of vascular aging in the continuum
of cardiovascular risk leading to hypertension.
3.3. Endothelial Replication and Apoptosis. Human aging is
accompanied by a degeneration of various tissues, which lose
part of their physiological functions. Apoptotic cell death
plays an important role during aging of various tissues in
vivo. Tissue damage due to age-dependent apoptosis has
beendocumentedinexperimentalanimalsforthebrain[27],
the inner ear [28], among others. It has been also described
that the regulation of programmed cell death plays an
important role for the ageing process in vivo. In this regard,
atherosclerosis, a major age-related disease of humans, is
accompanied by a degeneration of vascular endothelial cells
and vascular muscle cells due to programmed cell death
or apoptosis [29]. However, the mechanisms leading to
age-related apoptosis in an endothelial cell remains to be
clariﬁed. In this regard, Warner et al. demonstrated that
human endothelial cells followed a diﬀerent senescence
program from the program displayed by human ﬁbroblasts
[30].Theyfoundthatendothelial cellsshowedanage-related
increase in programmed cell death due to DNA rereplication
in the absence of mitosis with G1 arrest, leading in the
accumulation of “N” DNA content >4 in endothelial cells.
In this light of evidences, Asai et al. also postulated a
potential mechanism for the endothelial dysfunction based
on apoptosis, using a novel monkey model of aging, phy-
logenetically closer to humans but devoid of complications
secondary to associated cardiovascular diseases [31]. They
described an increased density of apoptotic cells observed
in the endothelium of the aorta and femoral artery in old
monkeys compared with young monkeys.
3.4. Oxidative Stress and Inﬂammation in Aging-Related
Diseases. As we have commented during the paper, aging is4 International Journal of Hypertension
the major risk factor for the development of cardiovascular
diseases and associated risk factors such as hypertension.
In this context, vascular oxidative stress and inﬂammation
signiﬁcantly increase with age as a consequence of greater
production of reactive oxygen species (ROS) and inﬂamma-
tory markers. One of the main consequences of increased
oxidative stress in aging is the functional inactivation of
nitric oxide (NO) induced by elevated concentrations of
superoxide anion, resulting in enhanced impairment of NO
bioavailability and decreased vasodilator capacity [32, 33].
In the same line, inﬂammation is considered a critical
initial step in the development of vascular disease during
aging. In this regard, recent studies have demonstrated
that arterial aging, in the absence of other known vascular
risk factors, is associated with a proinﬂammatory proﬁle
[34, 35]. This proinﬂammatory state induces, among others,
endothelial dysfunction by the upregulation of cellular adhe-
sion molecules (VCAM-1 and ICAM-1), and this enhanced
endothelial-leukocyte interactions and alterations in the
secretion of diﬀerent autocrine/paracrine factors which are
pivotal in inﬂammatory response. In this sense, it is well
known that the activation of transcriptional factors such as
nuclear factor-kappa β (NF-κB) are closely associated with
these deleterious eﬀects on vascular function [36]. In addi-
tion, NF-κB activation increases during aging and is thought
to be responsible of the increased expression of adhesion
molecules and inducible nitric oxide synthase found in
vascular wall [37]. TNFα signaling, mitochondrial ROS-
induced pathways and local renin angiotensin system are
knownpathwaysthatconvergewithNF-κBandcontributeto
the vascular dysfunctionality observed during aging-related
diseases.
Molecules strongly related to oxidative stress and aging
are advanced glycation end products (AGEs) [38, 39].
Initially, AGEs were considered associated with hyper-
glycemic states. However, later studies demonstrated that
AGEs formation may be stimulated even in normoglycemia
although its expression is exaggerated under diabetes. AGEs
are markers of carbonyl stress, which accumulates due
to an increased level of sugars and reactive dicarbonyl
compounds such as glucose, fructose, deoxyglucose glyoxal,
and triosephosphates. AGEs, also termed glycotoxins, are
well-known triggers of excess reactive oxygen species (ROS)
andabnormallyhighoxidative stress[40,41]thatdisruptthe
structural integrity of proteins altering their interaction with
other proteins and, therefore, aﬀecting its functionality
Large body of evidence has implicated AGEs as path-
ogenic mediators of the multiple complications associated
with aging and cardiovascular diseases, such as arterial stiﬀ-
ness, myocardial relaxation abnormalities, atherosclerotic
plaque formation, and endothelial dysfunction. In this sense,
AGEs have a wide range of pathological eﬀects, including
increased vascular permeability, inhibition of vascular dila-
tion by interfering with the nitric oxide (NO) pathway [42],
LDL oxidation [43], and macrophage and endothelial cell
activation to induce cytokine release and, thus, increase of
oxidative stress [44] .I nv i t r os t u d i e sh a v ed e m o n s t r a t e d
quenching and inactivation of NO by AGEs, modulating
NO activity and endothelium-dependent relaxation [45]. In
addition, AGEs also induce the production of ROS, which
favours the uncoupling of NO synthesis [46].Theyalsostim-
ulate the synthesis and release of proinﬂammatory cytokines
through the activation of NF-κB[ 47, 48]. In experimental
approaches,circulatinglevelsofAGEscorrelatewiththelevel
of diﬀerent oxidative and inﬂammatory biomarkers, such as
Cr e a c t i v ep r o t e i n[ 49]. Upon such inﬂammatory situation,
neutrophils, monocytes, and macrophages activate NADPH
oxidase, leading to AGEs generation [50]. Also, AGEs have
been shown to aﬀect platelet adhesion and aggregation,
thrombogenicity, and cell proliferation.
Recent ﬁndings have demonstrated that AGEs also are
capable to augment hyperglycemia-associated depletion in
endothelial nitric oxide production and endothelial nitric
oxide synthase, demonstrating its important role in vascular
dysfunction, linked to the induction of NO resistance [51].
This study observed an impaired vascular responsiveness
to acetylcholine, accompanied by decreased eNOS protein
expression and downregulation of cGMP-dependent protein
kinase-1 expression.
Another deleterious mechanism on vascular function
develop by AGEs is via the interaction with speciﬁc recep-
tors called RAGEs. These receptors are members of the
immunoglobulin superfamily that modulate the inﬂam-
matory response by increasing the expression of NF-κB,
proinﬂammatory cytokines, growth factors, and vascular
adhesion molecules [52].
With respect to hypertension, it has been observed that
AGEs diminish arterial compliance of large vessels elevating
systolic blood pressure and pulse pressure, via inducing
alterations in intima-media thickening and modifying col-
lagen and elastic ﬁbrils structure. Recent in vitro and in
vivo studies have shown that angiotensin II type 1 receptor
blockers can reduce AGEs formation [53, 54] although
many doubts still exit about the concrete mechanism by
which these molecules exerts this action. In summary, AGEs
provide a new target for the development of more potent
therapeutic agents in the treatment of vascular diseases.
In summary, the age-associated alterations in arterial
structure and functionality, such as endothelial dysfunction
and arterial stiﬀening, are considered as potent risk factors
for arterial diseases, even after accounting for traditional
cardiovascular risk factors, including arterial pressure.
4.New Molecular Mechanisms Associated with
Hypertension and Aging
As we have described above, aging is a major risk factor
for hypertension and cardiovascular disease. However, the
molecular mechanisms by which increased blood pressure
leads to vascular injury, and impaired endothelial function
are not well deﬁned. In recent years, new molecular mech-
anisms have appeared as possible targets to improve the
knowledge of this pathology. The new mechanisms pro-
posed include the eﬀect of telomere shortening, dysfunction
of progenitor cells, increase of deleterious microparticles,
and ﬁnally epigenetics and the involvement of life style
(Figure 2).International Journal of Hypertension 5
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Figure2:Newmechanismsinvolvedinhypertensionintheelderlypopulation.Telomereshortening,dysfunctionofprogenitorcells,increase
of platelet, leukocyte, erythrocyte, and endothelial cells-derived microparticles, and epigenetic alterations together with the involvement of
life style are proposed as new mechanisms associated with hypertension.
4.1. Telomeres Length. In the last years, the “telomere
hypothesis” of aging and its involvement in the development
of aging-related diseases such as hypertension has gained
importance [55]. Telomeres are distinctive DNA-protein
structures at the end of linear chromosomes that preserve
genomic integrity and progressively shorten with replication
[56]. Telomeres have demonstrated age-dependent short-
ening in proliferative somatic cells [57], and accumulative
evidence suggests that telomere length can be used as a
marker of biological aging of the cardiovascular system
and as a potential predictor of the risk and variability of
developing hypertension and cardiovascular events.
As telomere length becomes critically shortened, the
cellular replicative machinery stops functioning and usu-
ally leads to replicative senescence. Studies in telomerase-
deﬁcient mice have shown a direct link between telomere
shortening and hypertension [58]. In human studies, shorter
telomere length has been strongly associated with oxidative
stress [59], inﬂammation [60], atherosclerosis, and arterial
stiﬀness [61]. Results of the Framingham Heart Study have
also shown a reduced leukocyte telomere length in individ-
uals with a higher renin-to-aldosterone ratio, especially in
patients with hypertension [62]. In the same line, a ﬁve-
year follow-up study has shown shorter leukocyte telomere
length in hypertensive patients, who were also more likely
to develop in the future atherosclerotic artery disease [63].
Moreover, this study presented telomere length as an inde-
pendent risk factor for the development of cardiovascular
disease both in patients with hypertension and in patients
with normal blood pressure.
Interestingly, there are also diverse evidences showing
that some of the drugs used in the treatment of hypertension
stimulate telomerase activity and the reverse transcriptase
that adds telomere repeats onto the ends of chromosomes,
allowing the elongation of telomeres. The case of AT1
receptor antagonists of angiotensin II [64], statins [65], and
aspirin [66] is becoming, therefore, a new target for future
research studies.
During the last years, the number of studies about
progenitor cells and its involvement in the development and
evolution of vascular diseases has been increasing signiﬁca-
tively. In this sense, the ability of endothelial progenitor
cells to integrate into the vascular wall favouring endothelial
repair has been widely described. Aging-related diseases are
closely associated with endothelial injury and a signiﬁcative
reduction in the number and functionality of circulating
EPCS. Studies in mouse models have demonstrated a crucial
role of telomere shortening in the impairment of the
progenitor cells during biological aging. In this regard, a
recent study has shown that telomere shortening in EPCs
plays an important role in the pathogenesis of cardiovascular
disease via increased oxidative-related DNA damage [67].
In summary, telomere shortening could be a useful
biomarker of biological aging of the cardiovascular system
with a potent predictor value of the risk and variability6 International Journal of Hypertension
of developing hypertension and associated cardiovascular
events.
4.2. Progenitor Cells. As we have described previously,
endothelial dysfunction is thought to be critical in the devel-
opment of the vascular dysfunctionality observed in aging-
related diseases such as hypertension and cardiovascular
disease. Aging is related to the deleterious modiﬁcations
observed in vascular function. In addition, impairments
in endogenous vascular repair mechanisms, such as the
conducted by EPCs, are thought to contribute to the man-
ifestation of hypertension and cardiovascular disease. Bone
marrow-derived EPCs have been considered as important
agents of vascular repair. In addition, aging is associated with
reduced number and function of EPCs [68], contributing
to the greater cardiovascular risk observed in middle-aged
and older adults. However, the real inﬂuence of aging on the
increased EPCs apoptosis still remains unknown. Recently,
Kushner et al. have documented that aging is associated with
a proapoptotic EPC phenotype characterized by decreased
expression of key antiapoptotic proteins associated with
thePhosphoinositol-3-kinasesignalingpathwayandreduced
telomerase activity, contributing to the diminished ability of
EPCs to resist the apoptotic stimulus associated with aging
[69].
It has been argued that the reduced endothelial repair
capacity of EPCs in hypertensive patients is related to EPCs
senescence and impaired endothelial function and likely
representsanearlyeventinthedevelopmentofhypertension,
contributing to the end-organ damage associated to this
pathology [70, 71]. In this sense, infusions of circulating
EPCs have been found to be able to augment endothelium-
dependent vasodilatation, improving endothelial function
[72]. Both, animals and human studies have demonstrated
thattheimpairedEPCfunctionthatoccursduringhyperten-
sion can be corrected with some antihypertensive treatments
[73]. Therefore, it makes EPCs a modiﬁable factor that
provides a new interesting line of research in the treatment
of hypertension.
4.3. Circulating Microparticles. It was in 1967 when Wolf
described the presence of small circulating procoagulant,
prothrombotic, and proinﬂammatory particles in plasma
called microparticles [74]. Circulating microparticles are
small vesicular structures of about 0.1–1μm that have
been associated with arterial thrombotic processes [75].
Microparticles are shed from the surface of diﬀerent types
of cells in response to activation, injury, and/or apoptosis.
Although it is considered that the majority of circulating
microparticlesareplatelet-derived(70%–90%oftotal),other
cells such as red blood cells, leukocytes, and endothelial cells
also release microparticles.
Circulating microparticles are increased in patients with
cardiovascular risk factors such as hypertension [76]. In
this sense, increased number of circulating microparticles
has been associated with poor clinical outcome [77] and,
recently, microparticles have been deﬁned as potential prog-
nostic markers for vascular disease [78].
The inﬂuence of microparticles in vascular function,
favouring endothelial dysfunction, has been demonstrated
in multiple experimental studies. Microparticles have been
shown to induce the expression of endothelial cyclooxy-
genase type 2, diﬀerent adhesion molecules, the release of
cytokines, and the impairment of nitric oxide release from
vascular endothelial cells. Interestingly, these harmful eﬀects
on endothelial functionality seem to be mainly mediated
by microparticles of endothelial origin although platelet-
derived microparticles also mediate some of them. For this
reason, most of the studies have focused on microparticles
of endothelial origin as possible biomarkers of endotelial-
dysfunction in patients with vascular disease. In this regard,
when compared with classical markers of endothelial activa-
tion, endothelial derived microparticles appear to be more
robust predictor of the incidence of coronary events [79].
For instance, it has been shown that circulating endothelial
microparticles correlated positively with the extent and
severity of coronary stenosis at angiography in patients with
coronary syndromes [80].
It has been also observed that pharmacological treat-
ment aﬀects microparticle formation. While statins impair
endothelial microparticle formation, aspirin seems not to
aﬀect microparticle formation, and others such as ticlo-
pidine, abciximab, or cilostazol induced reduction in the
number of circulating microparticles [81, 82]. Therefore,
analysis of circulating microparticles could represent a
useful tool in monitoring the eﬃcacy of antihypertensive
treatments.
Increasing evidence indicates that changes in plasma
levels of microparticles of diﬀerent cellular origins might be
used as surrogate markers of vascular alterations, as those
that occur during hypertension. However, there are still
many questions of whether circulating levels of endothelial
microparticles are the cause or result of endothelial dys-
function, and more studies will be needed. Thus, due to
their procoagulant, prothrombotic, and proinﬂammatory
eﬀects on vasculature, microparticles could modulate the
cross-talk between the cellular elements of the coagulative,
thrombotic, and inﬂammatory systems through the transfer
ofdiﬀerentsignalingmoleculesandreceptorsoftheircellular
origin to other cell types. Therefore, the study of circulating
microparticles could be considered as novel therapeutic
target in cardiovascular diseases. In this regard, novel pro-
teomic approaches represents a new interesting tool for the
study of the concrete microparticle composition, facilitating
the identiﬁcation of active components and clarifying their
involvement in the development of diseases. In this context,
the ﬁrst proteomic studies analyzing the proteomic pattern
of platelet [83], red blood cells [84], and endothelial cells-
derived microparticles have already appeared [85].
4.4. Epigenetics and Lifestyle. Despite the considerable
knowledge gained in recent years on the human genome,
there are many questions regarding the mechanisms of
inheritance and the mechanisms involved in hypertension
and cardiovascular diseases. Nowadays, is fully accepted that
the development of diseases is very directly involved with
both genetic and epigenetic alterations.International Journal of Hypertension 7
In this regard, it is well known that genes are expressed
or not depending on various factors such as chromatin and
certain biochemical conditions, such as methylation of DNA
and modiﬁcation of histones. The science that studies all
these factors is called epigenetics. It is important to realize
that epigenetic processes are natural and essential for many
body functions, but if they occur improperly they can cause
serious adverse health eﬀects, and hence the relevance of
epigenetics in the study of human disease.
Epigenetics studies the interaction of DNA and its
expression with the environment. It consists in the study
of the inheritance of gene expression patterns that are
not determined simply by the genetic sequence of each
individual. It includes the study of any process that alters
gene activity without changing DNA sequence and leads to
changes that can be transmitted to daughter cells. We can
say that epigenetics acts as “interlocutor” with the genetics
andenvironment,helping toexplaintheactionoflifestyleon
the genes. It also describes the mechanisms that allow cells to
respond quickly to environmental changes, thus providing a
clear link between genes and the environment around them.
Hypertension is an arterial wall disease that together
with smoking, high cholesterol, diabetes, overweight, and
sedentary lifestyle is one of the main modiﬁable risk factor
that leads to the development of cardiovascular diseases.
Environmental factors such as diet, stress, and inactivity
directly aﬀect the incidence of this pathology, but it has
also been established that stress in utero may program
the later development of the disease. To date, the car-
diovascular eﬀects of early nutritional changes have been
largely investigated following maternal undernutrition or
protein restriction [86]. In this regard, interestingly, studies
have shown that in maternal low-protein diet rat model,
administration of angiotensin converting enzyme inhibitors
or angiotensin receptor antagonists in early life can prevent
the development of hypertension [87]. Epigenetic analysis
demonstrated that the proximal promoter of the AT1b
gene in the adrenal is signiﬁcantly undermethylated. In
vitro studies showed that the expression of this gene is
highly dependent on promoter methylation, suggesting a
link between fetal insults to epigenetic modiﬁcation of genes
and ultimately leading to the development of hypertension.
Similarly, the methylation pattern of a serine protease
inhibitor gene in human placenta is shown to be a marker
for preeclampsia-associated hypertension.
The hallmark of hypertension in the elderly is increased
vascular resistance. The usual therapeutic approach to the
elderly hypertensive patient should generally consist of a
reductioninsaltandcaloricintakeandanincreaseinaerobic
exercise. It has been demonstrated the eﬀectiveness of mod-
iﬁcations in the lifestyle to reduce blood pressure in aging
patients. For instance, the Nonpharmacologic Interventions
in the Elderly trial (TONE) demonstrated that with small
reduction in salt or corporal weight, it is possible to reach
a signiﬁcantly reduction of blood pressure levels [88]. In
thissense,epigeneticsstudiescouldprovidenewinformation
about the eﬀect of the environmental factors that are involve
in the development of cardiovascular diseases.
Nowadays, most of epigenetic studies are being con-
ducted in the area of oncology, which are getting plenty of
evidence linking epigenetic processes in cancer development.
However, in the cardiovascular area, there is a great deal of
untappedinformation.Therefore,epigeneticsoﬀerapromis-
ingavenueofinvestigationofthemechanismsinvolvedinthe
development and evolution of cardiovascular diseases.
5. Summary
In the elderly population hypertension is a signiﬁcant
determinant of cardiovascular risk, and nowadays, it is
well known that is closely associated with the incidence of
vascular events. The development of vascular endothelial
dysfunction is thought to be critical in the development of
the vascular dysfunctionality observed in hypertension. In
recent years, new molecular mechanisms such as telomere
shortening, dysfunction of progenitor cells, increase of
deleterious microparticles, and epigenetics alterations have
appeared as possible targets to improve the knowledge of
this pathology. Knowing more in depth the critical molec-
ular mechanisms underlying the vascular dysfunctionality
associated to hypertension may provide novel interventional
treatments for promotion of cardiovascular health in older
persons.
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